The low overall yield (1%) clearly must be addressed in order to support early clinical studies and supply the market. This was largest challenge and arose from a series of low yielding steps tied to installation of the chiral piperazine and acrylamide. Reducing the LLS step-count would also further streamline and debottleneck production.